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Abstract
Elevated Notch ligand and receptor expression has been associated with aggressive forms of prostate cancer, sug-
gesting a role for Notch signaling in regulation of prostate tumor initiation and progression. Here, we report a critical
role for Lunatic Fringe (Lfng), which encodes an O-fucosylpeptide 3-β-N -acetylglucosaminyltransferase known to
modify epidermal growth factor repeats of Notch receptor proteins, in regulation of prostate epithelial differentiation
and proliferation, as well as in prostate tumor suppression. Deletion of Lfng in mice caused altered Notch activation
in the prostate, associatedwith elevated accumulation of Notch1, Notch2, and Notch4 intracellular domains, decreased
levels of the putative Notch3 intracellular fragment, as well as increased expression of Hes1, Hes5, and Hey2. Loss of
Lfng resulted in expansion of the basal layer, increased proliferation of both luminal and basal cells, and ultimately,
prostatic intraepithelial neoplasia. The Lfng-null prostate showed down-regulation of prostatic tumor suppressor gene
NKX3.1 and increased androgen receptor expression. Interestingly, expression of LFNG and NKX3.1 were positively
correlated in publically available human prostate cancer data sets. Knockdown of LFNG in DU-145 prostate cancer cells
led to expansion of CD44+CD24− and CD49f+CD24− stem/progenitor-like cell population associated with enhanced
prostatosphere-forming capacity. Taken together, these data revealed a tumor-suppressive role for Lfng in the prostate
through differential regulation of Notch signaling.
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Introduction
Prostate cancer is the most common malignancy in males. Despite
recent progress on defining the cellular origin of prostate cancer
and oncogenic events associated with tumor initiation, it remains
unclear how the normal prostatic epithelial hierarchy is established
and maintained and how it is subverted during oncogenic transfor-
mation of prostate tissue. In recent years, Notch has emerged as a
critical regulator of epithelial differentiation and proliferation in
the prostate [1–5]. Indeed, Notch1 is selectively expressed in basal
epithelial cells, and elimination of Notch1-expressing cells inhibited
the branching morphogenesis, growth, and differentiation of early
postnatal prostate in culture and impaired prostate regeneration fol-
lowing hormone replacement in castrated mice [3,4]. Interestingly,
expression of a Notch1 gain-of-function allele during mouse embryo-
genesis or postnatal prostate development induced proliferation and
expansion of the progenitor cells in basal epithelium, whereas loss of
Notch signaling through deletion of canonical Notch transcriptional
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effector RBPJκ led to decreased cell proliferation and loss of epi-
thelial progenitors [2]. Paradoxically, a recent study showed that
Notch signaling may suppress proliferation and expansion of basal
stem/progenitor cells during regeneration of the murine prostate
tissue [5]. Thus, Notch signaling plays complex roles during
development, homeostasis, and regeneration of the prostate gland.
Fringe genes code for O-fucosylpeptide 3-β-N -acetylglucosaminyl-
transferases that can add N -acetylglucosamine to O-linked fucose
residues on epidermal growth factor repeats of Notch [6]. This mod-
ification modulates specificity and sensitivity of Notch receptors for
different ligands. Therefore, Fringes are powerful regulators of ligand-
mediated Notch signaling. There are three Fringe genes in mammals,
namely, Lunatic Fringe (Lfng),Manic Fringe, and Radical Fringe [7,8].
Expression of Lfng in the prostate is relatively low compared with
Manic Fringe and Radical Fringe but more restricted to basal epithe-
lium [5]. Given the existence of multipotent basal progenitors during
prostate postnatal development, regeneration, and homeostasis [9,10]
and the fact that Notch signaling regulates basal cell proliferation
and differentiation, Lfng may control Notch activation in these cells.
Because the prostate basal cell is a cell of origin for prostate cancer in
both mouse and human [10–14], modulation of Notch signaling by
Lfng in these cells could play a critical role in prostate tumor initiation
and/or progression. Interestingly, Lfng-dependent Notch signaling
controls basal stem/progenitor cell self-renewal and differentiation
in mammary gland, and Lfng deficiency induces basal-like breast
cancer [15]. We therefore sought to test for similar activities of this gene
in prostate gland.
In an attempt to define the function of Lfng in the prostate, we
studied activation of different Notch receptors in the Lfng-null pros-
tate as well as epithelial development in this context. Our data show
that Lfng inhibits activation of Notch1 and Notch4 in basal cells of
the mouse prostate gland while enhancing Notch3 activation. This is
associated with increased expression of Nkx3.1 tumor suppressor
gene and prevention of basal stem/progenitor cell expansion and
prostatic intraepithelial neoplasia (PIN) formation. In the human
prostate cancer cell line DU-145, LFNG knockdown increased cancer
stem/progenitor cell activity. Finally, a positive correlation was ob-
served between expressions of LFNG and NKX3.1, as well as negative
correlation between LFNG expression and Gleason scores in human
prostate cancer data sets. Thus, Lfng gene deficiency or silencing may
contribute to prostate cancer initiation through Notch-dependent
expansion of normal basal stem/progenitor cells and promote tumor
progression through Notch-dependent enrichment of cancer stem/
progenitor cells.
Materials and Methods
Histology and Immunohistochemistry
The Lfng−/− mice have been previously described [16]. Formalin-
fixed paraffin-embedded prostate tissues were processed for histology
and immunohistochemistry by standard procedures. Staining was
carried out on two sections per prostate from at least three mice
for each group, and representative images were acquired with a
Nikon Eclipse 80i microscope (Nikon, Melville, NY). Primary anti-
bodies used for immunohistochemistry were Notch1 (1:100; Cell
Signaling Technology, Danvers, MA, No. 3608), Notch4 (1:100;
Millipore, Billerica,MA, 09-089), cytokeratin 14 (K14) (1:200; Panomics,
Santa Clara, CA, E2624), cytokeratin 5 (K5) (1:1600; Covance,
Princeton, NJ, PRB-160P), cytokeratin 8 (K8) (1:800; Covance, MMS-
162P), smooth muscle actin α (Sma) (1:200; Abcam, Cambridge, MA,
ab5694), p63 (1:100; Santa Cruz Biotechnology, Dallas, TX, sc-8431),
aldehyde dehydrogenase (Aldh1) (1:100; Abcam, ab52492), and Ki-67
(1:100; Abcam, ab16667).
Western Blot Analysis
Prostate tissues were homogenized and lysed in RIPA buffer (Boston
BioProducts, Ashland, MA) supplemented with protease inhibitor
(Roche, Indianapolis, IN). Supernatants were clarified by centrifuga-
tion, and total protein was quantified. Whole-cell lysates from DU-
145 cells were prepared using the same buffer. Equivalent protein
amounts from experimental and control lysates were loaded for
Western blot analysis, performed according to standard methodology.
Prostate tissues from three pairs of wild-type and mutant littermates
were analyzed with similar results. Primary antibodies used for Western
blot analyses were Notch1 (1:1000; Cell Signaling Technology,
No. 3608), Cleaved Notch1 (1:1000; Cell Signaling Technology,
No. 4147), Notch2 [1:2000; Developmental Studies Hybridoma
Bank (DSHB), University of Iowa (Iowa City, IA), C651.6DbHN],
Cleaved Notch2 (1:1000; Abcam, ab52302), Notch3 [1:1000;
Proteintech Group (Chicago, IL), 55114-1-AP], Notch4 (1:1000;
Millipore, 07-189), Cleaved Notch4 [1:1000; GeneTex (Irvine, CA),
GTX86910], Hes1 (1:1000; Millipore, AB5702), pan-Akt (1:1000;
Cell Signaling Technology, No. 4691), Phospho-Akt (Ser473)
(1:1000; Cell Signaling Technology, No. 4060), PTEN (1:1000;
Cell Signaling Technology, No. 9188), Smad2 (1:1000; Cell Signaling
Technology, No. 5339), Phospho-Smad2 (Ser465/467) (1:1000;
Cell Signaling Technology, No. 3101), c-Met (1:1000; Cell Signaling
Technology, No. 3127), and androgen receptor (AR) (1:1000; Santa
Cruz Biotechnology, sc-816). Blots were reprobed with anti–β-actin
antibody (1:4000; Santa Cruz Biotechnology, sc-81178) as control for
equal loading.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Total RNA was prepared from anterior prostate glands or cultured
cells using RNeasy Mini Kit (Qiagen, Valencia, CA,) and reverse
transcribed using iScript cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA). Quantitative reverse transcription–polymerase chain
reaction (RT-PCR) was performed on a Bio-Rad CFX96 Real-Time
System using the RT2 SYBR Green qPCR Mastermixes (Qiagen).
We used primer sequences for mouse Hes1, Hes5, Hey1, Hey2, and
Klkb1 and human LFNG, HES1, HES5, HEY1, and HEY2 as pre-
viously reported [17–20]. Mouse Nkx3.1 primer sequences were
5′TGTCTTTGCCAGCCCTGAA (forward) and 5′TAGTATACACG-
GAGACCAAGGAGGTA (reverse). The relative abundance of mRNA
for each gene to GAPDH was determined by the equation 2−ΔCT
(ΔCT = threshold cycle (CT)Tested Gene − CTGAPDH). Data were
derived from triple reactions for each sample.
Generation of Stable LFNG Knockdown Cell Lines
The LFNG-small hairpin RNA (shRNA) construct in retroviral red
fluorescent protein (RFP) vector targeting 5′-AGCAGGTGACGCT-
GAGCTACGGTATGTTT-3′ sequences of human LFNG gene was
purchased from OriGene Technologies (Rockville, MD). DU-145
cells were transfected with the LFNG-shRNA plasmid or the scrambled
shRNA plasmid using FuGENE 6 Transfection Reagent (Promega,
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Madison, WI). Stable cell lines expressing LFNG-shRNA or scrambled
shRNA were established by selection with 1 μg/ml Puromycin (Sigma,
St Louis, MO).
Cell Proliferation and Prostatosphere Formation Assays
DU-145 cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS. CellTiter96 AQueous One Solution
Cell Proliferation Assay kit (Promega) was used for cell proliferation
assay, according to the manufacturer’s instructions. For prostatosphere
formation assays, DU-145 cells from monolayer cultures were re-
suspended in serum-free Dulbecco’s modified Eagle’s medium/F12
supplemented with MEGM SingleQuot Kit (Lonza, Allendale, NJ,
CC-4136) and plated onto individual wells of ultralow-attachment
six-well plate (2 × 103 cells in 2 ml per well) (Corning, Tewksbury, MA).
The spheres formed after 2 weeks of culture were quantified using Celigo
cytometer (Brooks, Chelmsford, MA). Secondary sphere formation was
tested by replating trypsin-dissociated cells from primary spheres.
Flow Cytometry Analysis
Flow cytometry was performed by standard procedures using
the following fluorochrome-conjugated antibodies: PE-Cyanine7
Anti-Human/Mouse CD44 (1:80; eBioscience, San Diego, CA,
25-0441), PE-Cy7 anti-human/mouse CD49f (1:20; BioLegend,
San Diego, CA, 313621), and Alexa Fluor 488 anti-human CD24
Figure 1. Deletion of Lfng caused dysregulation of Notch signaling in the prostate. (A) Western blot analysis for Notch receptors, Hes1,
and Smad proteins in prostate tissues from 10-week-old wild-type and Lfng−/− mice. (B) Quantitative RT-PCR of Notch downstream
targets Hes1, Hes5, Hey1, and Hey2 in prostates of 10-week-old mice. ***P < .001. (C) Immunofluorescence staining of Notch1,
Notch4, Notch1/K14, and Notch4/K14 in prostate sections from 10-month-old mice. Insets are high magnification images showing
Notch1 and Notch4 staining in cell membrane and cytoplasm. Arrows point to cells showing costaining of Notch1 and K14 and Notch4
and K14, respectively. Scale bars, 50 μm.
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(1:20; BioLegend, 311108). Fluorescence was recorded using Gallios
Flow Cytometer (Beckman Coulter, Indianapolis, IN) and analyzed
with Kaluza (Beckman Coulter) flow cytometry analysis software
version 1.2.
Analysis of LFNG Expression in Human Prostate Cancer
The Memorial Sloan Kettering Cancer Center (MSKCC) data
set was downloaded from http://cbio.mskcc.org/cancergenomics/
prostate/data/. The MSKCC_PCa_mRNA_data.txt file was used
without further processing. Values in column PathGGS, combined
Gleason score in the radical prostatectomy specimen, were used as
Gleason scores for correlation analysis. Only normal and primary cancer
samples were used in LFNG and NKX3.1 gene expression correla-
tion analyses. The Cancer Genome Atlas (TCGA) prostate cancer
RNA Sequencing (RNA-seq) and clinical data were downloaded from
the Broad Firehose (The Broad Institute, Cambridge, MA) website
(https://confluence.broadinstitute.org/display/GDAC/Dashboard-
Stddata) (November release, 2013). All plots and analyses were done
using R (http://www.r-project.org/).
Statistics
All data are presented as means ± SEs. Statistical analysis was per-
formed using the two-tailed Student’s t test. P value of .05 or less was
considered statistically significant.
Results
Lfng Regulates Notch Signaling in the Prostate
Multiple Notch ligands, receptors, and Fringes are expressed in
murine prostate epithelia [5]. To test for Lfng control of Notch receptor
activation in this context, we analyzed Notch intracellular domain
(NotchICD) accumulation in prostate glands of adult Lfng mutant
(Lfng−/−) mice [16]. Western blot analysis using antibody for cleaved
Notch1 (Val1744) or cleaved Notch2 (Asp1733) revealed a dramatic
increase in the level of Notch1ICD (∼110 kDa) as well as Notch2ICD
(∼110 kDa). The mutant glands also showed elevated levels of
Notch4 C-terminal peptide that are consistent in size with Notch4ICD
(∼68 kDa). In contrast, decreased levels of a putative Notch3 intra-
cellular protein fragment (∼100 kDa) were observed in the mutant
glands (Figure 1A). Thus, Lfng differentially regulates activation
through different Notch receptors in the prostate gland. Next, we
assessed mRNA levels of selected Notch downstream targets by quan-
titative RT-PCR. In agreement with increased accumulation of
Notch1, Notch2, and Notch4 intracellular domains, the mutant gland
showed dramatically increased levels of Hes5 and Hey2 mRNA and
Hes1 mRNA to a lesser extent (Figure 1B). We also performed
immunofluorescence staining for Notch1 and Notch4 receptors, in
combination with a basal cell marker K14. Consistent with theWestern
blot analysis results, Lfng−/− glands showed accumulation of cells with
very high levels of Notch1 and Notch4 proteins. Interestingly, most, if
not all, Notch1+ and Notch4+ cells expressed K14 (Figure 1C), indi-
cating that Notch1- and Notch4-expressing cells are located in the basal
epithelium. Notch activation can facilitate a transforming growth factor
β (TGFβ)–mediated positive feedback loop in the murine prostate by
upregulating TGFβ ligands and receptors [5]. Indeed, we detected
elevated levels of phospho-Smad2, but not total Smad2 proteins, in
Lfng mutant prostates (Figure 1A). Thus, loss of Lfng in the prostate
leads to hyperactivated signaling through Notch1, Notch2, and Notch4,
as well as enhanced activation of the TGFβ pathway.
Deletion of Lfng Caused Expansion of the
Basal Cell Compartment
The basal prostate epithelial compartment contains multipotent
stem/progenitor cells [9,10]. Intriguingly, deletion of Lfng caused
hyperactivation of Notch1 and Notch4 receptors in this layer (see
above). We therefore investigated whether Lfng-regulated Notch
signaling plays a role in self-renewal and/or differentiation of basal
stem/progenitor cells of the prostate gland. Immunostaining for
K14 and p63 demonstrated a remarkable increase in the number
of basal lineage cells in adult Lfng−/− mutant prostates (Figure 2, A
and B). We next stained for another basal cell marker, K5, and a
luminal cell marker, K8. The mutant gland showed a small increase
in the number of K5+ basal cells and more intense K8 staining in
luminal cells (Figure 2, A and B). By comparing K5 and K14 stain-
ing, it is clear that extra basal cells in Lfng mutants are mostly K14+
rather than K5+. Interestingly, a lineage-tracing study by Ousset
and colleagues revealed a higher frequency of labeled luminal cells
after marking K14+ cells as opposed to K5+ cells, suggesting that
K14+ basal cells are less restricted in their multilineage potential than
K5+ basal cells [9,21]. Thus, deletion of Lfng resulted in expansion of
basal cells, in particular, of the K14+ bipotential progenitor cells. Stem/
progenitor cells in the prostate gland show high levels of ALDH activity
[22]. Indeed, Lfng−/− prostates contained a dramatically increased
number of Aldh1+ cells, most of which were basally located (Figure 2,
A and B). c-Met is specifically expressed in basal and intermediate
cells of the prostate, and activation of c-Met induced a stemlike pheno-
type in human prostate cancer [23,24]. Interestingly, the Lfng mutant
gland showed dramatically increased c-Met protein level, suggesting
an accumulation of basal and/or intermediate cells. Taken together,
examination of expressions of multiple basal stem/progenitor cell
markers revealed an expansion of the basal cell compartment in Lfng-
null prostate.
Notch signaling has also been shown to regulate differentiation of
smooth muscle cells in the prostate [2]. We therefore examined
smooth muscle differentiation by staining for Sma. Both wild-type
and Lfng−/− mutant prostates showed a single layer of smooth muscle
cells surrounding most epithelial ducts (Figure 2D). However, three
of four mutant glands contained abnormal ducts with a large number
of glandular structures showing basally located Sma+ cells (Figure 2D,
inset), suggesting that Notch hyperactivation caused enhanced smooth
muscle cell specification, differentiation, or recruitment.
Increased Epithelial Proliferation and PIN in the
Lfng-Null Mutant Gland
PIN, a form of carcinoma in situ, is thought to represent a pre-
cursor of prostate adenocarcinoma. We followed male Lfng−/− mutants
for an extended period of time and found that the majority developed
PIN, starting at 6 months of age (Figure 3A). Lfng-null prostates
show largely intact overall architecture, where prostatic epithelial cells
are fully contained within the ducts. However, the mutant glands
contain multiple layers of atypical cells, which appear to have increased
nuclear size and nuclear pleomorphism. In some cases, foci of atypical
cells almost filled the ductal lumen. Unlike prostatic adenocarcinoma,
in which abnormal cells spread beyond the boundary of ducts and
form clusters without basal cell layer, Lfng-null glands show expansion
of basal cell layer. Using the criteria established by Park et al. [25], we
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determined that 13 of 15 Lfng-null mice (86.7%) developed low- to
high-grade PIN (PIN1 to PIN3) at 6 to 12 months of age, whereas
only 1 of 12 age-matched wild-type or Lfng+/− animals (8.3%)
showed low-grade PIN (PIN1). The difference between these two
groups is statistically significant (χ2 test, P < .001). Immunostaining
showed that up to 8% of epithelial cells were Ki-67+ in Lfng mutant
glands, whereas less than 1% of cells were proliferating in prostates
from wild-type littermates (Figure 3B). Because Lfng gene deletion
caused expansion of the basal compartment, we used double labeling
to identify dividing cells. Only 15% of Ki-67+ cells were K14+ (basal
cell marker), whereas 80% were positive for K8 (luminal cell marker).
This was true not only in Lfng mutants but also in wild-type glands
Figure 2. Deletion of Lfng caused expansion of basal compartment in the prostate. (A) Immunohistochemistry for K14, p63, Aldh1, and
K5/K8 in prostates from 10-month-old wild-type and Lfng−/− mice. (B) Quantification of labeled cells. K14+, p63+, Aldh1+, and K5+ cells
are quantified and normalized as percentage of total cells. Data are presented as means ± SEs derived from staining of two sections per
prostate from three mice of each group. **P < .01 and ***P < .001. (C) Western blot analysis of c-Met in wild-type and Lfng−/− prostate
tissues. (D) Anti-Sma staining in 10-month-old prostates. Occasional Sma staining in intraductal cells in the Lfng−/− prostate is shown by
the rectangle and its high magnification image to the right. Scale bars, 50 μm in A and 100 μm in D.
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where few proliferating cells were found in either layer (Figure 3C ).
Thus, deletion of Lfng resulted in increased proliferation of basal as
well as luminal cells.
The Nkx3.1 homeobox gene is a key regulator of prostate epithe-
lial cell differentiation and proliferation. Loss of Nkx3.1 function is
an initiating event in prostate carcinogenesis in mouse models and an
early event in humans [26–28]. By quantitative RT-PCR, we found
that Lfng−/− glands expressed Nkx3.1 at 40% the level seen in wild-
type glands (Figure 4A). In addition, Lfng mutant prostates showed
up to seven-fold increased expression of Klkb1, a prostate-specific
antigen (PSA)-related murine gene, in agreement with the report that
NKX3.1 negatively regulates PSA promoter activity in humans [29].
We also detected increased levels of phospho-Akt in mutant glands
(Figure 4B). Nkx3.1 has been shown to negatively regulate Akt
activity through an AR/PI3K-dependent pathway [30]. Indeed, Lfng
mutant prostates showed increased overall AR levels as indicated by
Western blot analysis, consistent with a previous finding that Nkx3.1
negatively modulates AR transcription (Figure 4C ) [30]. Immunohis-
tochemistry demonstrated higher intensity of AR staining in the major-
ity of luminal cells from Lfng mutant glands compared to luminal cells
from wild-type prostates. However, mutant glands showed accumula-
tion of a small number of AR−K8+ luminal cells, in addition to expan-
sion of the basal compartment as noted above (Figure 4C ). Thus,
dysregulated Notch signaling due to loss of Lfng resulted in elevated
AR expression in the majority and silencing of AR in a small subset
of luminal compartment cells. Given that Pten level in the Lfng−/− pros-
tate was unchanged (Figure 4B), down-regulation ofNkx3.1may be the
key event leading to Akt activation. Interestingly,Nkx3.1 promoter con-
tains a putative RBPJκ-binding element (data not shown), suggesting
that an RBPJκ-dependent Notch signal may be responsible for al-
tered regulation of Nkx3.1.
Positive Correlation between LFNG and NKX3.1 Expressions
in Human Prostate Cancer
Lfng controls Notch activation in the mouse prostate, and deletion
of Lfng resulted in basal cell expansion as well as PIN, suggesting a
tumor-suppressive function for Lfng in this tissue. We therefore
analyzed LFNG expression in two human prostate cancer gene
Figure 3. Increased epithelial proliferation and PIN in the Lfng−/− prostate. (A) Histology of anterior prostates from wild-type and Lfng−/−
mice at 10 months of age. To the right is a high-magnification image of the area inside the rectangle. (B) Anti–Ki-67 staining in prostate
sections of 10-month-old mice. (C) Immunofluorescence staining of K14/Ki-67 and K8/Ki-67 in prostates. Labeled cells are quantified and
presented as percentage of Ki-67+ cells of total cells, K14+ among Ki-67+ cells, and K8+ among Ki-67+ cells, respectively. Data are
derived from two sections per prostate from three animals of each group. Scale bars, 100 μm in A and 50 μm in B and C.
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Figure 5. Scatterplots for LFNG and NKX3.1 gene expressions in human primary prostate cancers and normal prostate tissues from two
public data sets. Pearson correlation analysis showed positive correlation between LFNG expression and NKX3.1 expression: 0.43 for
the MSKCC data set (left; P = 1.52e-8, 160 samples) and 0.45 for TCGA data set (right; P < 2.2e-16, 301 samples).
Figure 4. Down-regulation of Nkx3.1, increased AR expression, and elevated Akt phosphorylation in the Lfng−/− prostate. (A) Quantitative
RT-PCR of Nkx3.1 and Klkb1 in prostates of wild-type and Lfng−/− mice at 10 weeks of age. *P < .05 and ***P < .001. (B) Western blot
analysis for Akt, phospho-Akt, and Pten in prostate tissues from 10-week-old mice. (C) Anti-AR staining, Western blot analysis of AR, and
double immunofluorescence staining of AR/K8. Black arrow points to accumulation of AR-negative basal cells. White arrows point to a
small number of AR-negative, K8-positive luminal cells. Scale bars, 50 μm.
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Figure 7. Knockdown of LFNG in DU-145 cells caused expansion of cancer stem/progenitor-like cells. (A) Proliferation assay for DU-145 cells
stably expressing LFNG-shRNA or scrambled control in monolayer culture. (B) Prostatosphere formation assay for control and experimental
DU-145 cells. Shown are representative photographs and quantification of secondary spheres formed after 2 weeks of culture. ***P< .001.
(C) Representative flow cytometry analysis of CD24/CD49f and CD24/CD44 in control and experimental DU-145 cells.
Figure 6. Knockdown of LFNG in DU-145 cells caused elevated Notch3 activation. (A) Western blot analysis for Notch receptors in DU-145
cells stably expressing LFNG-shRNA or scrambled control. Duplicate of cell lysates was loaded for each sample. (B) Quantitative RT-PCR
of LFNG and Notch downstream targets HES1, HES5, HEY1, and HEY2 in these cells. Triple reactions were carried out for each sample.
*P < .05, **P < .01, and ***P < .001.
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expression data sets available from public sources, namely, MCKCC
[31] and TCGA (http://cancergenome.nih.gov/cancersselected/
prostatecancer) data sets. Gene expression correlation analysis showed
a positive association between LFNG and NKX3.1 gene expressions
in both data sets (MSKCC data set: Pearson correlation r = 0.43,
P value = 1.52e-8; TCGA data set: Pearson correlation r = 0.45,
P value < 2.2e-16) (Figure 5). Interestingly, negative correlations
between LFNG expressions and prostate cancer Gleason scores were
observed in both data sets: −0.17 for the MSKCC data set (Kendall
correlation, P value = 0.014) and −0.16 for the TCGA data set
(P value = 0.0084). Although the correlation between LFNG gene
expressions and Gleason scores is not strong, together with the results
from our mouse experiments, these data suggest that LFNG may play
a tumor-suppressive role in human prostate cancers as well.
LFNG Suppresses In Vitro Tumorsphere Formation in
Human Prostate Cancer Cells
To test the role of LFNG in human prostate cancer cells, we used
shRNA to suppress LFNG expression in the DU-145 cell line
(Figure 6B). Knockdown of LFNG caused only slight increase in cell
proliferation in two dimensional (2D) culture (Figure 7A); however,
it significantly increased prostatosphere-forming capacity (Figure 7B).
Indeed, flow cytometry analysis showed an expansion of stem/
progenitor cell–enriched CD44+CD24− and CD49f+CD24− popula-
tions in LFNG knockdown cells (Figure 7C ) [24,32]. Thus, Lfng
can inhibit self-renewal of stem/progenitor-like cells in the prostate
under normal physiological condition as well as in the prostate cancer
cell population. Interestingly, unlike germline deletion of Lfng in mice,
LFNG knockdown in DU-145 cells resulted in increased accumulation
of putative intracellular domain of Notch3 (Figure 6A) and increased
expression of the Notch target genes HES1 and HEY1 (Figure 6B).
Thus, although Lfng appears to suppress self-renewal of normal and
cancer stem cells in the prostate, this may involve different Notch
receptors and ligands during tumor initiation and progression.
Discussion
Prostate basal stem/progenitor cells are efficient targets for prostate
cancer initiation [10–12,14]. Here, we show that deletion of Lfng
caused a dramatic expansion of prostate basal stem/progenitor cells.
Interestingly, the mutant glands showed increased expression and
activation of Notch1 and Notch4 in basal cells (Figure 1, A and
C ). Given that both Jagged-family ligands, Jagged1 and Jagged2,
are highly expressed in basal cells [5], Lfng likely inhibits Jagged-
mediated activation of Notch1/Notch4 in these cells, thereby block-
ing their proliferation. Indeed, forced expression of a constitutively
active Notch1ICD in the postnatal prostate using PB-Cre4 caused
expansion of the basal compartment [2]. Interestingly, expression
of the same Notch1ICD allele using APR2PB-Cre resulted in a de-
creased number of basal cells [5]. The apparent discrepancy between
these studies may arise from use of different Cre-expression deleter
strains. PB-Cre4 may cause Notch1ICD expression in prostate epi-
thelium as well as in stroma, which may indirectly influence basal
cell activity [33]. In our study, Lfng is deleted in the whole animal,
and its effect on prostate basal cell activity may also involve cell-
autonomous and non–cell-autonomous functions. In fact, a recent
report showed that Lfng can repress Notch activity in neighboring
cells by modulating Dll1 function [34]. In this context, Lfng could
function in the stromal cells to repress Notch activation in adjacent
basal cells of prostatic epithelium.
In addition to the expansion of basal compartment, the Lfngmutant
prostate showed hyperproliferation of luminal cells and PIN formation.
This could occur through differentiation of basal stem/progenitor
cells into luminal progenitor cells during postnatal development [9].
The Lfng mutant prostate may contain increased number of luminal-
committed basal cells and/or unipotent luminal progenitors, leading
to increased proliferation in the luminal compartment. Loss of Lfng
could have a direct impact on luminal cell differentiation and pro-
liferation. Whereas Notch2 is highly expressed in basal as well as
luminal compartment, Notch1 and Notch4 are preferentially basal,
and Notch3 is the only Notch receptor that is almost exclusively lumi-
nal [5]. Intriguingly, Lfng−/− prostates showed a decreased level of
putative Notch3 intracellular domains (Figure 1A), suggesting that
Lfng-dependent Notch3 signaling might regulate luminal cell differen-
tiation and/or proliferation.
We observed differential regulation of Notch receptor activation
by Lfng in the mouse prostate gland and in a human prostate cancer
cell line. For instance, Lfng−/− mutant gland showed elevated
Notch1, Notch2, and Notch4 signaling but decreased Notch3 acti-
vation, whereas increased NOTCH3 activation occurred in response
to LFNG gene knockdown in DU-145 cells. The reason for this is
not clear. However, the result is not particularly surprising in that 1)
Fringe proteins control activation of multiple Notch receptors in
response to multiple ligands, 2) expression of specific Notch ligands
and receptors is noted in different cells within the prostate epithelial
hierarchy as well as in different stages of tumor progression, and 3)
multiple cell types and layers interact in vivo, whereas this complexity
is lost in cell lines grown in vitro.
Several studies have implicated dysregulated Notch activation in
prostate cancer [35–38]. Negative correlation between LFNG expres-
sion and Gleason scores in human prostate cancer suggests that
LFNG may function as a tumor suppressor through modulation of
Notch signaling. Our functional analyses of Lfng in the mouse pros-
tate as well as in human prostate cancer cell line support a tumor-
suppressive role for this gene. Lfng may suppress tumor initiation
by preventing basal cell expansion and PIN formation through inhib-
iting Jagged-mediated Notch1/Notch4 signaling in basal compart-
ment and facilitating Notch3 signaling in luminal cells. Interestingly,
the Lfng-null mice rarely develop invasive prostate tumor (only one case
in more than 40 animals monitored), suggesting that prostate tumori-
genesis in these mice is subject to restraint by other signaling pathways
such as TGFβ (Figure 1A) [39]. Lfng may also suppress tumor pro-
gression through inhibition of Notch-dependent cancer stem cell
enrichment. In addition, down-regulation of a known prostatic tumor
suppressor gene Nkx3.1 in the Lfng−/− prostate, as well as positive cor-
relation between expressions of LFNG and NKX3.1 in human prostate
cancer, reinforces Lfng as a tumor suppressor and suggests that Lfng-
mediated regulation of Notch may well represent a node for thera-
peutic intervention of the disease. Although LFNG gene mutations
do not typically occur in human prostate cancer, this study highlights
the importance of LFNG in regulation of Notch signaling within the
prostatic stem/progenitor hierarchy and as a potent suppressor of
inappropriate stem cell self-renewal.
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